Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, “CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,”1 re.

Business Wire • 17 hours ago

LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that members of the Company's Executive Leadership Team will provide general business updates during fireside chats at the four following November healthcare conferences: UBS Global Healthcare Conference on Mon., Nov. 9, from 11-11:35 a.m. EST in Palm Beach, Fla. 8th Annual Wolfe Research Healthcare Conference on Tues., Nov. 10, from 9:20-9:50 a.m. EST in New York City.

Business Wire • Oct 21, 2026

LivaNova to Announce Third-Quarter 2026 Results

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call.The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the.

Business Wire • Sep 23, 2026

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

LivaNova Director Sells 1,650 Shares for $131,500

The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.

The Motley Fool • Sep 11, 2026

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City: Morgan Stanley 24th Annual Global Healthcare Conference on Mon., Sept. 14, from 11:30 a.m.-12:05 p.m. EDT Baird 2026 Global Healthcare Conference on Tues., Sept. 15, from 11:25-11:55 a.m. EDT Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial.

Business Wire • Sep 3, 2026

Artisan International Small-Mid Fund Q2 2026 Portfolio Review

Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.

Seeking Alpha • Aug 24, 2026

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

Zacks Investment Research • Aug 6, 2026

LivaNova Q2 Earnings Call Highlights

LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.

MarketBeat • Aug 5, 2026

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026